Blank Cover Image

Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib

フォーマット:
論文
責任表示:
Terashima, Takeshi ; Yamashita, Tatsuya ; Arai, Kuniaki ; Sunagozaka, Hajime ; Kitahara, Masaaki ; Nakagawa, Hidetoshi ; Kagaya, Takashi ; Mizukoshi, Eishiro ; Honda, Masao ; Kaneko, Shuichi
言語:
英語
出版情報:
Blackwell Publishing / 日本肝臓学会 Japan Society of Hepatology, 2014-11-01
著者名:
Terashima, Takeshi
Yamashita, Tatsuya
Arai, Kuniaki
Sunagozaka, Hajime
Kitahara, Masaaki
Nakagawa, Hidetoshi
Kagaya, Takashi
Mizukoshi, Eishiro
Honda, Masao
Kaneko, Shuichi
続きを見る
掲載情報:
Hepatology Research
ISSN:
1386-6346  CiNii Research  Webcat Plus  JAIRO
巻:
44
通号:
12
開始ページ:
1179
終了ページ:
1185
バージョン:
author
概要:
Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, although there is no proven therapeutic procedure following the termination of sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for patients with advanced HCC as subsequent therapy. Methods: We retrospectively evaluated 27 consecutive patients with advanced HCC who were treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. Cisplatin (20 mg/m2 per day) was administered via the hepatic artery for 10 min, prior to the continuous administration of 5-fluorouracil (330 mg/m2 per day) over 24 h from days 1-5 and 8-12 and the s.c. administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five patients (18.5%) experienced device-related complications. No unexpected adverse reactions and no treatmentrelated deaths were observed. Partial response was obtained in eight patients (29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, respectively. Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is a potentially useful treatment procedure in patients with advanced HCC even after failure of sorafenib. 続きを見る
URL:
http://hdl.handle.net/2297/40612
タイトル・著者・出版者が同じ資料

類似資料:

1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 

Hayashi, Tomoyuki, Yamashita, Taro, Terashima, Takeshi, Suda, Tsuyoshi, Okada, Hikari, Asahina, Yoshiro, Hayashi, …

BioMed Central Ltd.

Mizukoshi, Eishiro, Nakagawa, Hidetoshi, Kitahara, Masaaki, Yamashita, Tatsuya, Arai, Kuniaki, Sunagozaka, Hajime, Iida, …

Elsevier

Terashima, Takeshi, Yamashita, Tatsuya, Takata, Noboru, Nakagawa, Hidetoshi, Toyama, Tadashi, Arai, Kuniaki, Kitamura, …

Blackwell Publishing Ltd.

Takata, Yoshiko, Nakamoto, Yasunari, Nakada, Akiko, Terashima, Takeshi, Arihara, Fumitaka, Kitahara, Masaaki, Kakinoki, …

Elsevier

Mizukoshi, Eishiro, Yamashita, Tatsuya, Arai, Kuniaki, Terashima, Takeshi, Kitahara, Masaaki, Nakagawa, Hidetoshi, Iida, …

Springer Science and Business Media Deutschland GmbH

Nakamoto, Yasunari, Mizukoshi, Eishiro, Kitahara, Masaaki, Arihara, Fumitaka, Sakai, Yoshio, Kakinoki, Kaheita, Fujita, …

Blackwell Publishing

Yamashita, Tatsuya, Arai, Kuniaki, Sunagozaka, Hajime, Ueda, Teruyuki, Terashima, Takeshi, Yamashita, Taro, Mizukoshi, …

Karger

Mizukoshi, Eishiro, Yamashita, Tatsuya, Arai, Kuniaki, Sunagozaka, Hajime, Ueda, Teruyuki, Arihara, Fumitaka, Kagaya, …

Wiley-Blackwell

Sunagozaka, Hajime, Honda, Masao, Yamashita, Taro, Nishino, Ryuhei, Takatori, Hajime, Arai, Kuniaki, Yamashita, Tatsuya, …

Wiley-Blackwell

Terashima, Takeshi, Mizukoshi, Eishiro, Arai, Kuniaki, Yamashita, Tatsuya, Yoshida, Mariko, Ota, Hajime, Onishi, Ichiro, …

Springer Science and Business Media Deutschland GmbH

Terashima, Takeshi, Yamashita, Tatsuya, Arai, Kuniaki, Kawaguchi, Kazunori, Kitamura, Kazuya, Yamashita, Taro, Sakai, …

Japanese Cancer Association / Blackwell Publishing Ltd

Mizukoshi, Eishiro, Fushimi, Kazumi, Arai, Kuniaki, Yamashita, Tatsuya, Honda, Masao, Kaneko, Shuichi

John Wiley and Sons